Maxim Group Believes Adamis Pharma (NASDAQ: ADMP) Won’t Stop Here

By Carrie Williams

In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on Adamis Pharma (NASDAQ: ADMP), with a price target of $10. The company’s shares opened today at $4.40, close to its 52-week high of $4.80.

Kolbert noted:

“Adamis announced this past January that the FDA has accepted for review the NDA for its Epinephrine Pre-filled Syringe “PFS.” The FDA indicated that it considered the resubmission to be a complete response to the CRL.”

According to, Kolbert is ranked 0 out of 5 stars with an average return of -15.7% and a 29.4% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Arbutus Biopharma Corporation, and ContraVir Pharmaceuticals Inc.

Adamis Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $10.

Based on Adamis Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $3.04 million and GAAP net loss of $5.77 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $6.41 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamis Pharmaceuticals Corp. is a pharmaceutical company engages in the provision of medical development. Its activities include the combination of specialty pharmaceuticals and biotechnology to produce medicines for patients, and physicians. It focuses on products such as inhaler technology in the field of allergy and respiratory diseases. The company was founded on April 1, 2009 and is headquartered in San Diego, CA.

  • Bill

    Jason Kolbert needs to update his picture. He looks like he’s high. That combined with the “0 star” rating, -15.7% avg return, and 29.4% success rate makes me wonder how an article like this even gets written. I guess you can find absolutely anything on the internet.